# Praxis Precision Medicines, Inc.

**PRAX**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001689548


# None

**No letter**

5 of 13 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $937.9M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, thin data, degenerate inputs<br>not computable: fortress balance sheet |
| **Inputs computable** | 5 of 13 |
| **Graded from** | filings received through Feb 19, 2026<br>276 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026 |
| **Last close** | $300.65<br>2026-11-20; market equity $8.4B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 19, 2026*

We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 51.4** | | | | | | |
| Gross profitability | not computable | 32.8% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.6% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Accruals ratio | (7.6%) | (6.7%) | | 51.4 | 756 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 11.7** | | | | | | |
| Altman Z double-prime | 12.98 | 0.31 | | 6.7 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (3.61x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 10.22x | 2.68x | | 16.8 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 37.2** | | | | | | |
| Revenue growth, three-year compound | not computable | 9.6% | | | | |
| *four annual observations are required; found 3* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 33.9% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | 101.2% | 3.2% | | 2.4 | 663 | 2025-12-31 |
| Net share issuance, one year | 38.1% | 1.6% | | 72.0 | 626 | 2026-02-16 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 38.1% |
| Thin data | 5 of 13 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-11-20 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 46.5% | (1.7%) | 78 |
| Distance from 52-week high | (22.2%) | (33.0%) | 63 |
| EBIT to enterprise value | not computable | 0.5% | |
| Free cash flow yield | (3.0%) | 0.6% | 37 |
| Book value to price | 0.15 | 0.29 | 31 |
| Sales to price | 0.00 | 0.38 | 0 |
| Composite equity issuance, five years | 238.6% | 13.5% | 94 |
| Relative strength against the sector, log excess return | 0.21 | (0.19) | 78 |
| Twelve-month failure probability, CHS model | 0.05% | 0.06% | 45 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $361.9M |
| Operating cash flow, four quarters | -$321.8M |
| Months of runway | 13.5 |
| Days since last periodic filing | 13 (10-Q received Nov 9, 2026) |
| Median daily dollar volume, 63 sessions | $129.8M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$303.3M | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$249.1M | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 3 | assets | us-gaap:Assets | $937.9M | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 4 | assets | us-gaap:Assets | $483.1M | 2024-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 5 | current assets | us-gaap:AssetsCurrent | $610.9M | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $59.8M | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$1.1B | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$326.2M | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 9 | book equity | us-gaap:StockholdersEquity | $878.1M | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 10 | liabilities | us-gaap:Liabilities | $59.8M | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 11 | revenue | us-gaap:Revenues | $0 | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 12 | revenue | us-gaap:Revenues | $8.6M | 2024-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 13 | revenue | us-gaap:Revenues | $2.4M | 2023-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 14 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $56,000 | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 15 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$131.8M | 2024-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 16 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $0 | 2024-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 17 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$111.1M | 2023-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 18 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $50,000 | 2023-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$185.0M | 2022-12-31 | 2024-03-05 | 10-K | 24-000034 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $444,000 | 2022-12-31 | 2024-03-05 | 10-K | 24-000034 |
| 21 | depreciation amortization | us-gaap:Depreciation | $140,000 | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 22 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$302.8M | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 23 | income tax | us-gaap:IncomeTaxExpenseBenefit | $471,000 | 2025-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 24 | current assets | us-gaap:AssetsCurrent | $404.4M | 2024-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $37.5M | 2024-12-31 | 2026-02-19 | 10-K | 26-000029 |
| 26 | assets | us-gaap:Assets | $87.9M | 2023-12-31 | 2025-02-28 | 10-K | 25-000040 |
| 27 | assets | us-gaap:Assets | $115.1M | 2022-12-31 | 2024-03-05 | 10-K | 24-000034 |
| 28 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 27,850,833 | 2026-02-16 | 2026-02-19 | 10-K | 26-000029 |
| 29 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 20,163,250 | 2025-02-26 | 2025-02-28 | 10-K | 25-000040 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.